US OptionsDetailed Quotes
ADBE241213C380000
- 103.05
- 0.000.00%
15min DelayClose Dec 13 16:00 ET
0.00High0.00Low
103.05Open103.05Pre Close0 Volume0 Open Interest380.00Strike Price0.00Turnover0.00%IV3.73%PremiumDec 13, 2024Expiry Date85.69Intrinsic Value100Multiplier-1DDays to Expiry17.36Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma5.48Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Adobe Stock Discussion
Sign in to post a comment
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...
+2
7
1
1
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drug...
+2
1
$Adobe (ADBE.US)$ The OI put/call ratio has dropped considerably. It being under 1 could mean good news for next week. ![]()
1
2
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Adobe (ADBE.US)$ shud sell you before earning. Lousy shit
2
$Adobe (ADBE.US)$ earnings where great did they have bac giudence ? why down
1
1
$Adobe (ADBE.US)$ Legging in here at 458.8
$Adobe (ADBE.US)$ hope the fall will stop 448, if not, then 433 for real, wait to load up
2
3
$Adobe (ADBE.US)$ wow someone said 460, now its really 460! hahaha
1
1
$Adobe (ADBE.US)$ green candle next pls
2
$Adobe (ADBE.US)$ any chance rebounce back above 500?
2
1
No comment yet
10xStockPicks OP : This is the correctly edited research report. Previous article has a few typos. Special thanks to Fund manager John for his notes. Please do your own research. I firmly believe ESPR will be a solid bet.